INTERVENTION 1:	Intervention	0
Trastuzumab Emtansine (All Participants)	Intervention	1
This cohort (Cohort 1) enrolled all participants with HER2 positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.	Intervention	2
adjuvant	CHEBI:60809	262-270
disease	DOID:4,OGMS:0000031	393-400
INTERVENTION 2:	Intervention	3
Trastuzumab Emtansine (Asian Participants)	Intervention	4
This cohort (Cohort 2) enrolled Asian race participants with HER2-positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.	Intervention	5
adjuvant	CHEBI:60809	269-277
disease	DOID:4,OGMS:0000031	400-407
Inclusion Criteria:	Eligibility	0
HER2-positive disease determined locally	Eligibility	1
disease	DOID:4,OGMS:0000031	14-21
Histologically or cytologically confirmed invasive breast cancer	Eligibility	2
breast cancer	DOID:1612	51-64
Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent	Eligibility	3
breast cancer	DOID:1612	20-33
adjuvant	CHEBI:60809	41-49
Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy	Eligibility	4
adjuvant	CHEBI:60809	201-209
Measurable and/or non-measurable disease	Eligibility	5
disease	DOID:4,OGMS:0000031	33-40
Left ventricular ejection fraction (LVEF) >/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)	Eligibility	6
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2	Eligibility	7
group	CHEBI:24433	29-34
Adequate organ function	Eligibility	8
organ	UBERON:0000062	9-14
function	BAO:0003117,BFO:0000034	15-23
Use of highly effective contraception as defined by the protocol	Eligibility	9
Exclusion Criteria:	Eligibility	10
History of treatment with trastuzumab emtansine	Eligibility	11
history	BFO:0000182	0-7
Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not	Eligibility	12
Peripheral neuropathy of Grade >/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0	Eligibility	13
peripheral neuropathy	HP:0009830,DOID:870	0-21
cancer	DOID:162	50-56
History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer	Eligibility	14
history	BFO:0000182	0-7
carcinoma	HP:0030731,DOID:305	90-99
carcinoma	HP:0030731,DOID:305	141-150
skin carcinoma	DOID:3451	136-150
uterine cancer	DOID:363	160-174
breast cancer	DOID:1612	226-239
History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria	Eligibility	15
history	BFO:0000182	0-7
hormone	CHEBI:24621	133-140
History of exposure to cumulative doses of anthracyclines	Eligibility	16
history	BFO:0000182	0-7
History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade </=1) prior to first study treatment.	Eligibility	17
history	BFO:0000182	0-7
acute	HP:0011009,PATO:0000389	125-130
Metastatic central nervous system (CNS) disease only	Eligibility	18
central nervous system	UBERON:0001017	11-33
disease	DOID:4,OGMS:0000031	40-47
Brain metastases which are symptomatic	Eligibility	19
brain	UBERON:0000955	0-5
History of a decrease in LVEF to less than (<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment	Eligibility	20
history	BFO:0000182	0-7
congestive heart failure	HP:0001635,DOID:6000	66-90
History of symptomatic CHF (New York Heart Association [NYHA] Classes II-IV) or serious cardiac arrhythmia requiring treatment	Eligibility	21
history	BFO:0000182	0-7
heart	UBERON:0000948	37-42
arrhythmia	HP:0011675	96-106
History of myocardial infarction or unstable angina within 6 months of first study treatment	Eligibility	22
history	BFO:0000182	0-7
myocardial infarction	HP:0001658,DOID:5844	11-32
Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy	Eligibility	23
dyspnea	HP:0002094	8-15
Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)	Eligibility	24
severe	HP:0012828	8-14
disease	DOID:4,OGMS:0000031	38-45
disease	DOID:4,OGMS:0000031	110-117
Pregnancy or lactation	Eligibility	25
lactation	GO:0007595	13-22
Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus	Eligibility	26
active	PATO:0002354	16-22
immunodeficiency	HP:0002721	44-60
virus	BAO:0000232	61-66
virus	BAO:0000232	86-91
virus	BAO:0000232	108-113
hepatitis b	DOID:2043	74-85
hepatitis c	DOID:1883	96-107
History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product	Eligibility	27
history	BFO:0000182	0-7
hypersensitivity	GO:0002524,DOID:1205	64-80
product	BAO:0003067	139-146
Outcome Measurement:	Results	0
Percentage of Participants With Adverse Events of Primary Interest (AEPIs)	Results	1
The AEPIs in this study were defined as the following: adverse events (AEs) Grade >/= 3, specifically, hepatic events, allergic reactions, thrombocytopenia and hemorrhage events, all Grade >/= 3 AEs related to trastuzumab emtansine and pneumonitis events of all grades.	Results	2
thrombocytopenia	HP:0001873,DOID:1588	139-155
Time frame: Baseline up to approximately 7 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Trastuzumab Emtansine (All Participants)	Results	5
Arm/Group Description: This cohort (Cohort 1) enrolled all participants with HER2 positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.	Results	6
adjuvant	CHEBI:60809	285-293
disease	DOID:4,OGMS:0000031	416-423
Overall Number of Participants Analyzed: 2002	Results	7
Measure Type: Number	Results	8
Unit of Measure: Percentage of Participants  23.1        (21.2 to 25.0)	Results	9
Results 2:	Results	10
Arm/Group Title: Trastuzumab Emtansine (Asian Participants)	Results	11
Arm/Group Description: This cohort (Cohort 2) enrolled Asian race participants with HER2-positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.	Results	12
adjuvant	CHEBI:60809	292-300
disease	DOID:4,OGMS:0000031	423-430
Overall Number of Participants Analyzed: 181	Results	13
Measure Type: Number	Results	14
Unit of Measure: Percentage of Participants  51.4        (43.9 to 58.9)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 427/2002 (21.33%)	Adverse Events	1
ANAEMIA 13/2002 (0.65%)	Adverse Events	2
BONE MARROW FAILURE 1/2002 (0.05%)	Adverse Events	3
bone marrow	UBERON:0002371	0-11
DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%)	Adverse Events	4
disseminated intravascular coagulation	HP:0005521,DOID:11247	0-38
FEBRILE NEUTROPENIA 1/2002 (0.05%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	8-19
THROMBOCYTOPENIA 11/2002 (0.55%)	Adverse Events	6
thrombocytopenia	HP:0001873,DOID:1588	0-16
ACUTE CORONARY SYNDROME 3/2002 (0.15%)	Adverse Events	7
acute coronary syndrome	HP:0033678	0-23
ANGINA PECTORIS 1/2002 (0.05%)	Adverse Events	8
angina pectoris	HP:0001681	0-15
CARDIAC ARREST 1/2002 (0.05%)	Adverse Events	9
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
CARDIAC FAILURE 1/2002 (0.05%)	Adverse Events	10
CARDIAC TAMPONADE 1/2002 (0.05%)	Adverse Events	11
cardiac tamponade	HP:0033415,DOID:115	0-17
Adverse Events 2:	Adverse Events	12
Total: 36/181 (19.89%)	Adverse Events	13
ANAEMIA 0/181 (0.00%)	Adverse Events	14
BONE MARROW FAILURE 0/181 (0.00%)	Adverse Events	15
bone marrow	UBERON:0002371	0-11
DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%)	Adverse Events	16
disseminated intravascular coagulation	HP:0005521,DOID:11247	0-38
FEBRILE NEUTROPENIA 0/181 (0.00%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	8-19
THROMBOCYTOPENIA 10/181 (5.52%)	Adverse Events	18
thrombocytopenia	HP:0001873,DOID:1588	0-16
ACUTE CORONARY SYNDROME 1/181 (0.55%)	Adverse Events	19
acute coronary syndrome	HP:0033678	0-23
ANGINA PECTORIS 0/181 (0.00%)	Adverse Events	20
angina pectoris	HP:0001681	0-15
CARDIAC ARREST 0/181 (0.00%)	Adverse Events	21
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
CARDIAC FAILURE 0/181 (0.00%)	Adverse Events	22
CARDIAC TAMPONADE 0/181 (0.00%)	Adverse Events	23
cardiac tamponade	HP:0033415,DOID:115	0-17
